Repurposing antiviral drugs against HTLV-1 protease by molecular docking and molecular dynamics simulation.
HTLV-1
drug repurposing
molecular docking
molecular dynamics (MD) simulation
protease
Journal
Journal of biomolecular structure & dynamics
ISSN: 1538-0254
Titre abrégé: J Biomol Struct Dyn
Pays: England
ID NLM: 8404176
Informations de publication
Date de publication:
07 2023
07 2023
Historique:
medline:
14
6
2023
pubmed:
26
5
2022
entrez:
25
5
2022
Statut:
ppublish
Résumé
Human T-cell leukemia virus type I (HTLV-1) belongs to the delta retrovirus family and the etiological agent of adult T-cell leukemia (ATL(. While the current HTLV-1 therapy, relies on using Zidovudine plus IFN-γ, there is no FDA approved drugs against it.
Identifiants
pubmed: 35612907
doi: 10.1080/07391102.2022.2078411
doi:
Substances chimiques
Antiviral Agents
0
HTLV-1 protease
EC 3.4.23.-
Simeprevir
9WS5RD66HZ
Saquinavir
L3JE09KZ2F
Atazanavir Sulfate
4MT4VIE29P
Aspartic Acid Endopeptidases
EC 3.4.23.-
Protease Inhibitors
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM